Navigation Links
Pegasys Study Authors Conclude that Patients Successfully Treated,for Hepatitis C Can be Considered ''Cured''

CV; the remaining eight patients tested positive for HCV, at an average of two years following the completion of treatment. The study found that these eight patients exhibited no consistency in age, gender or HCV genotype, and it has not been determined if these patients experienced a relapse or if they were re-infected with HCV.

"We at Roche are proud to be able to offer some hepatitis C patients the prospect of such a positive outcome with our currently-available therapies, but we also recognize the urgent need to further improve response rates," said Tom Klein, Vice President, Hepatology, Roche. "In addition to ongoing research with PEGASYS, Roche has the most comprehensive pipeline in the area, with four compounds currently in human development that target the virus in a number of different ways. The development of R1626 and partnerships with InterMune, Maxygen and Pharmasset, all underscore our long-term commitment to finding effective new therapies with the goal of successfully treating more patients with chronic hepatitis C."

About Hepatitis C

Hepatitis C is a blood-borne infectious disease of the liver and a leading cause of cirrhosis, liver cancer and the need for liver transplants. According to the Centers for Disease Control and Prevention (CDC), an estimated 4.1 million Americans (1.6 percent) have been infected with hepatitis C; 3.2 million are chronically infected. The number of new infections per year has declined from an average of 240,000 in the 1980s to about 26,000 in 2004. CDC estimates the number of hepatitis C-related deaths could increase to 38,000 annually by the year 2010, surpassing annual HIV/AIDS deaths.

About PEGASYS

PEGASYS, in combination with COPEGUS, are indicated for the treatment of adults with chronic hepatitis C who have compensated liver disease and have not previously been treated with interferon alpha. Efficacy has been demonstrated in patients with compensated liver disease and histological
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Data Suggest that Pegasys May be an Option in Hepatitis C Patients Unable to Tolerate Peg-Intron
2. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
3. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
4. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
11. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
Post Your Comments:
(Date:3/27/2015)... , March 27, 2015 XRpro ... for drug discovery and development services which features ... the pharmaceutical industry, announced financial results for the ... Timothy C.  Tyson, Chairman of XRpro Sciences commented, ... successfully transition from development stage to commercial stage ...
(Date:3/27/2015)... 27, 2015  Valeant Pharmaceuticals International, Inc. (NYSE: ... its previously announced registered offering of common shares in ... Pursuant to the Offering, the Company issued 7,286,432 common ... aggregate gross proceeds of approximately $1.45 billion. On March ... and Exchange Commission a final prospectus supplement to its ...
(Date:3/27/2015)... NORTH HOLLYWOOD, Calif. , March 27, 2015 /PRNewswire/ ... quality of life of myeloma patients while working toward ... Brian Higgins (D-NY) for introducing a federal resolution ... month of March 2015 as "National Multiple Myeloma Awareness ... people living with myeloma worldwide, and more than 110,000 ...
Breaking Medicine Technology:XRpro Sciences Announces Fiscal 2014 Financial Results 2XRpro Sciences Announces Fiscal 2014 Financial Results 3XRpro Sciences Announces Fiscal 2014 Financial Results 4Valeant Pharmaceuticals Closes Offering Of $1.45 Billion Of Common Shares 2Valeant Pharmaceuticals Closes Offering Of $1.45 Billion Of Common Shares 3The International Myeloma Foundation (IMF) Secures the Introduction of a Federal Resolution Recognizing March 2015 as "National Multiple Myeloma Awareness Month" 2
... 13, 2011 U.S. Marshals, acting under a court ... on Jan. 5 and 6, seized all dental devices ... (Logo:   http://photos.prnewswire.com/prnh/20090824/FDALOGO ) ... an FDA inspection that found significant deficiencies in the ...
... Although 2010 brought healthcare reform, investors are wondering if ... expect some volatility in the sector, as the Republican-led ... through a repeal effort or withholding funding for portions ... Poor,s Equity Research. "Healthcare reform or ...
Cached Medicine Technology:U.S. Marshals Seize Dental Devices From Florida Manufacturer 2S&P Equity Research Issues Health Care Sector Predictions for 2011 2S&P Equity Research Issues Health Care Sector Predictions for 2011 3S&P Equity Research Issues Health Care Sector Predictions for 2011 4S&P Equity Research Issues Health Care Sector Predictions for 2011 5S&P Equity Research Issues Health Care Sector Predictions for 2011 6
(Date:3/27/2015)... (PRWEB) March 27, 2015 First Choice ... today. The new facility is located 12665 W Lake Houston ... a resident of Summerwood, I look forward to delivering the ... Dr. Sowell, Facility Medical Director of First Choice Emergency Room ... Emergency Room made a donation to Summer Creek High School ...
(Date:3/27/2015)... NY (PRWEB) March 27, 2015 Ticket Down is ... Concert in 2015. After a phenomenal and highly successful ... "Nashville" will be going out on tour again in 2015 and ... tour gets underway on April 29th in New York City at ... at the Comerica Theatre on May 10th. , Fans of the ...
(Date:3/27/2015)... PA and LONDON, UK (PRWEB) March 27, 2015 ... of DrugDev SiteStart Melissa (Liss) Easy was named to ... , The 40 Under 40 list spotlights 40 dynamic, ... their professional accomplishments and community involvement. Winners are honored ... a special supplement of the Philadelphia Business Journal. , ...
(Date:3/27/2015)... FL and London, UK (PRWEB) March 27, 2015 ... announced today that it has appointed Sean Fitzgerald, a ... role of Chief Operating Officer and Interim Chief Financial ... President of leading education technology innovator, EverFi, backed by ... Schmidt, and Twitter founder Evan Williams. Prior to EverFi, ...
(Date:3/27/2015)... 27, 2015 Operatic contenders and their ... on April 17th. The universally acclaimed baritone Sherrill Milnes ... annual Opera Idol at The Merion in Evanston. The ... has drawn aspiring opera singers from around the country. ... of the finest young talent in the country,” said ...
Breaking Medicine News(10 mins):Health News:First Choice Emergency Room Opens New Facility in Houston, Texas 2Health News:Nashville Live in Concert Tickets in New York, Boston, Washington, DC, Chicago, Minneapolis, San Francisco, Los Angeles and Phoenix Now On Sale at TicketDown.com 2Health News:DrugDev Founder Melissa Easy is 2015 Philadelphia Business Journal 40 Under 40 Honoree 2Health News:GenSight Appoints Former Technology Executive as Chief Operating Officer 2Health News:Opera Idol Competition At The Merion In Evanston 2
... of illicit drugs, but have got enchanted with prescription ... ,The MTF survey has been the concerted effort of ... most recent survey, collating information from 48,460 students from ... and 12th grades has revealed that marijuana use had ...
... over stressful conditions provide immunity// to face stressors which ... ,Scientists from National Institute of Mental Health (NIMH) ... inoculates against such hard knocks - the circuitry of ... executive hub, the prefrontal cortex, but also altered it ...
... in this week's PLoS Medicine suggest possible new avenues ... paper, researchers led by Dominique Mazier from the Laboratory ... novel compound, tazopsine, from a plant traditionally used against ... against the liver stages of human and mouse malaria. ...
... A variant gene has been identified by researchers that help ... gene seems to confer a preserving effect upon the mental ... from the Albert Einstein College of Medicine of Yeshiva University. ... ,Dr. Nir Barzilai, the lead researcher is the director of ...
... heart surgery years ago underwent the same procedure that ... is raring to get back to work after recuperating from ... vessel called aorta, in his heart ,that was torn. ... procedure for a condition called dissecting aortic aneurysm.As a young ...
... is a mint flavored sweetener, produced naturally by plants and ... an ingredient in chewing gum, toothpaste, mouthwash and other products. ... Service (ARS) and collaborators have developed a genetically engineered bacteria, ... used to produce Xylitol on a large scale. ...
Cached Medicine News:Health News:Prior Experience to Stress Acts as an Immunization 2Health News:You may Live Long and Think Clear With a Variant Gene 2Health News:Pioneer Heart Surgeon Faced the Scalpel at 98 2Health News:Xylitol To Be Produced By Genetically Engineered E. Coli 2
Shielding's new Surgical Drop Away / Flex Back Apron offers top of the shoulder velcro flaps for an adjustable fit. Features elastic back panels for added comfort and support. For quick removal apron...
Shielding's Standard Coat Apron with open back allows for freedom of movement, maximum flexibility and increased comfort....
This set includes 2 small, 1 medium, 1 large gonad shields and a belt. The shields and belt is an interchangeable system attached by velcro....
Lap pad used to protect pelvic regions...
Medicine Products: